Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes

School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA.
Journal of Occupational and Environmental Medicine (Impact Factor: 1.8). 06/2005; 47(5):447-52. DOI: 10.1097/01.jom.0000161727.03431.3e
Source: PubMed

ABSTRACT Diabetes is the third-most expensive physical health condition among US employees. We sought to evaluate the contribution of hypoglycemia to these costs.
We studied 2664 employees using insulin for whom medical encounters and short-term disability (STD) records were available.
Among these employees, 442 (16.6%) had a diagnosis of hypoglycemia during an average follow-up of 2.5 years. The risk of hospitalization and emergency room visits was increased twofold in this group. Much of this excess was associated with hypoglycemia. The annualized medical cost of hypoglycemia was $3241. Patients with hypoglycemia had 77% more STD days annually. The risk of STD in the week after hypoglycemia was increased fivefold.
These data suggest that hypoglycemia contributes substantially to medical care utilization and to disability-related work absence among employees using insulin.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:As the prevalence of diabetes mellitus (DM) continues to increase at an alarming rate, achieving glycosylated hemoglobin (AIC) target levels is crucial to prevent microvascular and macrovascular complications and to reduce the impact this disease has on individuals and society as a whole.
    Insulin 07/2006; 1(3):109-121. DOI:10.1016/S1557-0843(06)80020-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hispanics experience a higher rate of diabetes than non-Hispanic whites and tend to have worse glycemic control and a greater risk of diabetes-related complications. Once oral antidiabetic agents become insufficient, insulin plays an important role in achieving glycemic goals. However, many Hispanic patients are resistant to initiating insulin therapy or hesitant to increase doses, as necessary, to control their glucose levels. Barriers to insulin therapy include socioeconomic issues (eg, cost, insurance status), language difficulties, poor health literacy, and cultural beliefs that impact the patient-provider relationship and negatively affect patients' perceptions of diabetes and insulin. Healthcare providers can help overcome these issues and improve patient-provider communication by practicing culturally competent care. Implementation of a simple titration regimen using once-daily basal insulin may enable Hispanic patients to maintain glycemic control and improve outcomes.
    Southern Medical Journal 09/2007; 100(8):812-20. DOI:10.1097/SMJ.0b013e3180f609c4 · 1.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypoglycemia is a common consequence of achieving tight glycemic control for patients with type 2 diabetes, with clinical effects ranging from occasional mild discomfort to incapacitation, coma, or in rare cases, death. Severe hypoglycemic events, particularly those resulting in emergency medical intervention or hospitalization, incur substantial medical costs for patients and the healthcare system. Although vigilance is needed for the possibility of severe events, hypoglycemia need not be a barrier to effective glycemic control in type 2 diabetes. Data from clinical trials and meta-analyses have demonstrated that the basal insulin analog insulin glargine results in a reduced rate of severe hypoglycemic events compared with conventional insulin therapy such as neutral protamine Hagedorn (NPH) insulin. Overall, use of insulin glargine compared with NPH insulin appears to reduce the risk of nocturnal and severe hypoglycemia by 40% to 60% and may result in cost savings. Analyses of hypoglycemia rates from "real-world" clinical practice databases and retrospective analyses of medical claims data also have revealed reduced rates with insulin glargine, consistent with the findings from clinical trials.
    The American journal of managed care 02/2008; 14(1):25-30. · 2.17 Impact Factor